ImmuneWalk Therapeutics is a clinical-stage biotech focused on modulating immune and inflammatory disease through monocyte inhibition. Its core program centers on the discovery of a novel adhesion checkpoint that regulates migration of specific immune cells into inflamed tissues, a differentiated approach versus existing anti-inflammatory agents. The company's lead candidate, IW-601, is an engineered monoclonal antibody that demonstrated disease‑modifying activity in preclinical models of multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and metabolic dysfunction‑associated steatohepatitis. ImmuneWalk is conducting the POINTGUARD Phase 1 clinical trial; the Single Ascending Dose stage has been completed. The company plans to use the proceeds to expand operations and advance R&D. Multiple clinical and development catalysts are anticipated in 2025–2026.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

May 2025